Trotsky and Shag. First of all The 10k or annual report from Protokinetix dated June 30 is an amendment to the 10k released on the 14th of April for the year ended 31st of December 2003:
In other words for a period of time when PKTX had no verification of the RECAF site.
“Introduction.
This First Amended Form 10-KSB is being filed as a result of a calculation error in the number of issued and outstanding common shares as of the conclusion of the December 31, 2003 calendar year.
The number previously reported was 27,968,750, and the actual number of common shares issued and outstanding as of December 31, 2003 was 24,743,750, a difference of 3,225,000 shares FEWER than previously reported.”
They decided to get independent validation from Hopital Europeen Georges Pompidou, before initiating a cancer therapy based on the RECAF technology, which only makes sense.
Biocurex is of course happy to further get external or independent validation, as this would be important in order to get a license agreement.
Subsequently, on the positive preliminary data from Paris PKTX has decided to initiate their research:
May 20th Press release from PKTX:
“Based on these results, the Georges Pompidou Hospital will be proceeding to test the RECAF antibody on additional cancers. At this time, the ProtoKinetix Scientific Advisory Board is satisfied that these third-party validation results have confirmed the presence of the RECAF receptor site on cancer cells. ProtoKinetix will commence immediately with the design of a research program towards the development of a therapeutic agent.”
June 1st Press release from PKTX
“VANCOUVER, British Columbia, June 1, 2004 (PRIMEZONE) -- Dr. John Todd, President and CEO of ProtoKinetix (OTC BB:PKTX.OB - News), states, ``Confirmation by the Georges Pompidou Hospital that a clear binding of an antibody to the AFP receptor sites (RECAF(TM)) on certain cancer cells and no binding of the antibody to similar `normal' cells is validation of a unique characteristic about these kinds of cancer cells that sets them apart from healthy cells.”
“In parallel, continuing additional trials on RECAF will be ongoing to test all malignancies. The Company now has evidence that RECAF(TM) exists. Now we will use proven technology as we proceed towards the development of a potential cancer therapy.''
October 23 2003, Press release from BOCX
``Our initial studies indicate that the RECAF(tm) technology works on practically all types of cancer. However, we need to obtain independent validation for each cancer type. This process is time consuming; there are many different kinds of cancer. Therefore, as part of our overall strategy, we are engaging scientists in what can be best defined as a multi-centric, international study. The work to be done in France is necessary for the licensing of BioCurex's technology to European Biopharma companies.''
I hope this might help clear the picture a bit,
Cheers, A340
News 
Market Data 
Discover 
AI
